Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis.
about
Translational biomarkers of neurotoxicity: a Health and Environmental Sciences Institute perspective on the way forwardBiomarkers in Multiple Sclerosis: An Up-to-Date OverviewA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesMyelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosisSuppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46-62.Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradationExposure to the Epstein-Barr Viral Antigen Latent Membrane Protein 1 Induces Myelin-Reactive Antibodies In VivoDesign of targeted B cell killing agents.Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis.The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.Comparison of DNA-hydrolyzing antibodies from the cerebrospinal fluid and serum of patients with multiple sclerosis.Autoantibodies with enzymatic properties in human autoimmune diseases.Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosisUbiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunitySystemic lupus erythematosus: molecular cloning and analysis of 22 individual recombinant monoclonal kappa light chains specifically hydrolyzing human myelin basic protein.Systemic lupus erythematosus: molecular cloning and analysis of recombinant monoclonal kappa light chain NGTA2-Me-pro-ChTr possessing two different activities-trypsin-like and metalloprotease.Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.Liposome-encapsulated peptides protect against experimental allergic encephalitisIntroduction into PPPM as a new paradigm of public health service: an integrative view.Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients.High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients.Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesisAffinity and catalytic heterogeneity of polyclonal myelin basic protein-hydrolyzing IgGs from sera of patients with multiple sclerosisCD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation StudyVaried immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde.DNA-hydrolyzing Ab: is catalytic activity a clue for physiological significance?Clinical biomarkers in multiple sclerosis.Neuroproteomic profiling of human body fluids.Changes in haematopoietic progenitor colony differentiation and proliferation and the production of different abzymes in EAE mice treated with DNA.Autoantibody targets in vaccine-associated narcolepsy.Analysis of myelin basic protein fragmentation by proteasome.A human germ line antibody light chain with hydrolytic properties associated with multimerization status.Anti-histone H1 IgGs from blood serum of systemic lupus erythematosus patients are capable of hydrolyzing histone H1 and myelin basic protein.Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein.Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.Design of Chemical Conjugate for Targeted Therapy of Multiple Sclerosis Based of Constant Fragment of Human Antibody Heavy Chain and Peptoid Analog of Autoantigen MOG35-55.
P2860
Q23920632-F09A3B0C-594C-4FF0-81B2-078AF6B7D47CQ27496017-9BA84961-1BE0-4648-9F23-484A46FD1E92Q28068709-99AE770B-906E-4FE6-84D8-89301A86251CQ28910423-1D852D72-E621-4DB2-98AB-41BF72547505Q33509141-873D5988-0D5D-4330-B691-F4A74072A260Q33793002-870238CE-1C5A-499D-A74F-332804BD43D9Q33875219-4302C1CA-7DA5-4B07-B75E-CC3CEB2AB331Q33934041-32A6DDC3-E6EB-4CBF-A3C6-BFD4E2C4A67DQ34266957-04F7C0ED-C9D8-4461-8563-FC974765ACC3Q34677183-06B174CB-46D9-49F1-B818-5B0BF7C32AC0Q35149485-5815FB7D-DB9D-46A4-BA87-09000E336662Q35214200-155B1DE8-AB2D-4845-BF4A-CB393C9B1168Q35231795-0AE28BC3-477E-465A-A6ED-6CF297D175FBQ35551663-FD6D9F1E-4E37-4C22-A155-2C265EE4BBCCQ35600192-13BB4552-A1BD-489D-8F55-80848AA8306AQ35691336-71E600EB-264B-4195-84BE-F7D3B463A4BCQ35721504-6A27DD88-62DB-44DC-AA91-7ABCFC3F8EFBQ36022441-55568F91-6605-44A9-897D-C5A15C8096BCQ36482892-4A8B22C2-F180-4FF3-92B5-DCF2B1FA1BEFQ36588428-2C364CA0-D5AC-4EF4-AA8F-734449AF8007Q36666373-E22E9A81-7279-4E31-88F7-A4AF26812B13Q36778303-30E9507C-DDF6-4438-B76C-92ABA7C381A7Q36894072-7B562975-669E-4FA2-9732-E3EC6CBCB790Q37130888-E8ACD0CA-3E8A-459B-BE61-E4974AF33C50Q37296340-17723395-9FED-4355-A1A6-DC4C414E2FAAQ37368151-7A73C7E1-A74B-4680-89BE-EEA9E3E615DBQ37374547-49CE2DFC-CB7D-4DF8-914B-266FDE290AB0Q37400955-FFE20651-9820-4FC2-9097-113E8E0CE4C5Q37606394-50A82203-3C8A-425F-BA2F-F16A4321B737Q37610434-8F1F436C-E5D8-4916-8FA2-BEBF3E137C9FQ38088728-AB989E2D-7100-4F7D-8BC5-05FFCD7CD8A2Q38569255-309FB67A-9CDD-41A5-9FDB-E8C0838B9B8AQ38638486-EAAA5CBA-B468-4F15-BD58-1732C7D305F7Q40743940-73823F33-E0C6-44CC-B341-B9F62319A6A3Q42146009-3A2475B9-AC7C-439D-8CE9-FB5912547626Q42680119-AE3FD2A1-C0D2-4210-8B76-31F80943FFA1Q43003645-3D45A409-06E6-4FCF-A55B-A863ECFD766DQ43081690-155634BE-E367-4F22-9FA6-CCB5C293DC07Q43293662-E096C3E5-918D-4F7A-9EF0-5D7CD53A9660Q52674893-19B52B94-5807-4E5F-9F93-C522184524DD
P2860
Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Recognition and degradation of ...... marker for multiple sclerosis.
@ast
Recognition and degradation of ...... marker for multiple sclerosis.
@en
Recognition and degradation of ...... marker for multiple sclerosis.
@nl
type
label
Recognition and degradation of ...... marker for multiple sclerosis.
@ast
Recognition and degradation of ...... marker for multiple sclerosis.
@en
Recognition and degradation of ...... marker for multiple sclerosis.
@nl
prefLabel
Recognition and degradation of ...... marker for multiple sclerosis.
@ast
Recognition and degradation of ...... marker for multiple sclerosis.
@en
Recognition and degradation of ...... marker for multiple sclerosis.
@nl
P2093
P921
P1476
Recognition and degradation of ...... marker for multiple sclerosis.
@en
P2093
Alain Friboulet
Alexander G Gabibov
Alexander I Alehin
Alexey A Belogurov
Bérangère Avalle
Daniel Thomas
Ekaterina A Souslova
Herbert C Morse
Inna N Kurkova
Maria Yu Zakharova
P304
P356
10.4049/JIMMUNOL.180.2.1258
P407
P577
2008-01-01T00:00:00Z